Pillstats
Rx only · Solution/ Drops · Ophthalmic

Latanoprostene Bunod

Brands: Vyzulta · Latanoprostene Bunod

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCS01EE06
RxCUI (US)1988390
US makers1 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$29.43$58.86$88.29$117.71Dec 2025May 2026Jul 2026
$102.291
Latest avg · Jul 22, 2026
+3%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

2.2K4.3K6.5K8.6K2025 Q12025 Q22025 Q32025 Q42026 Q1
6.8K
Rx · 2026 Q1
24K
Units dispensed
-6%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Bausch & Lomb Incorporatedunknown4SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.